Enterprise Value

1.429B

Cash

143.7M

Avg Qtr Burn

-33.89M

Short % of Float

0.34%

Insider Ownership

0.39%

Institutional Own.

64.20%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
afami-cel (Afamitresgene autoleucel) (ADP-A2M4) Details
Myxoid/Round cell liposarcoma, Cancer

Big Mover™

Susp. Mover™

PDUFA

Approval decision

Phase 2

Data readout

Lete-cel (NY-ESO) Details
Sarcoma, Myxoid/Round cell liposarcoma

Phase 2

Data readout

Uzatresgene autoleucel (uza-cel)(ADP-A2M4CD8) (MAGE A4) +/- nivolumab Details
Bladder cancer, Head and neck cancer, Cancer, Solid tumor/s, Urothelial cancer

Phase 1

Data readout

Gavo-cel (TC-210) (Mesothelin) + nivolumab Details
Solid tumor/s, Ovarian cancer, Cancer

Failed

Discontinued

ADP-A2AFP Details
Hepatocellular carcinoma, Cancer

Failed

Discontinued

afami-cel (afamitresgene autoleucel) (ADP-A2M4) + pembro Details
Head and neck cancer, Homozygous familial hypercholesterolemia, Cancer, Solid tumor/s

Failed

Discontinued

TC-110 (CD19) Details
Non-Hodgkin lymphoma, Leukemia, Acute lymphoblastic leukemia, Diffuse large B cell lymphoma, Cancer

Failed

Discontinued

TC-510 Details
Cancer, Colorectal cancer , Ovarian cancer, Mesothelioma, Triple-negative breast cancer , Pancreatic cancer

Failed

Discontinued